• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment.

作者信息

Packer Milton

机构信息

Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Tex; Imperial College, London, UK.

出版信息

Am J Med. 2020 Jul;133(7):781-782. doi: 10.1016/j.amjmed.2020.01.016. Epub 2020 Feb 12.

DOI:10.1016/j.amjmed.2020.01.016
PMID:32061625
Abstract
摘要

相似文献

1
Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment.二甲双胍是否会干扰钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的心血管益处？关于其作为糖尿病治疗基石作用的疑问。
Am J Med. 2020 Jul;133(7):781-782. doi: 10.1016/j.amjmed.2020.01.016. Epub 2020 Feb 12.
2
Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin.与钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂通过拮抗瘦素保护心脏这一假说相反的观点
Diabetes Obes Metab. 2018 Jun;20(6):1367-1368. doi: 10.1111/dom.13234. Epub 2018 Feb 21.
3
Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?在治疗糖尿病时，我们应该联合使用GLP-1受体激动剂和SGLT2抑制剂吗？
Am J Med. 2018 May;131(5):461-463. doi: 10.1016/j.amjmed.2017.11.052. Epub 2018 Jan 5.
4
Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.钠-葡萄糖协同转运蛋白 2 抑制剂是否通过平衡瘦素的作用来预防射血分数保留的心力衰竭？一个新的假说。
Diabetes Obes Metab. 2018 Jun;20(6):1361-1366. doi: 10.1111/dom.13229. Epub 2018 Feb 20.
5
Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.在心血管结局试验中探索“MACE”，解读动脉粥样硬化性心血管疾病获益与心力衰竭获益的相关性。
Diabetes Obes Metab. 2019 Aug;21(8):1780-1789. doi: 10.1111/dom.13740. Epub 2019 Apr 29.
6
Using Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020.2020年使用胰岛素治疗控制不佳的2型糖尿病
JAMA. 2020 Jun 16;323(23):2419-2420. doi: 10.1001/jama.2020.1303.
7
Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs.降糖药物通过自噬依赖性和非依赖性途径调节糖尿病心脏的氧化应激和细胞器应激。
Cardiovasc Diabetol. 2020 May 13;19(1):62. doi: 10.1186/s12933-020-01041-4.
8
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂对2型糖尿病患者的心血管益处。
Med Lett Drugs Ther. 2019 Feb 25;61(1566):26-28.
9
First-line treatment for type 2 diabetes: is it too early to abandon metformin?2型糖尿病的一线治疗：现在放弃二甲双胍是否为时过早？
Lancet. 2020 Nov 28;396(10264):1705-1707. doi: 10.1016/S0140-6736(20)32523-X.
10
Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis.评估心血管疾病 2 型糖尿病患者使用二甲双胍和 SGLT2 抑制剂的终生获益：一项系统评价和两阶段荟萃分析。
Am J Cardiovasc Drugs. 2024 May;24(3):371-383. doi: 10.1007/s40256-024-00640-w. Epub 2024 Apr 8.

引用本文的文献

1
Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.SGLT2 抑制剂在 2 型糖尿病中的心血管获益、与二甲双胍的相互作用以及红细胞增多症的作用：一项自身对照病例系列研究。
Cardiovasc Diabetol. 2022 Jun 3;21(1):92. doi: 10.1186/s12933-022-01520-w.
2
Effect of Metformin on T2D-Induced MAM Ca Uncoupling and Contractile Dysfunction in an Early Mouse Model of Diabetic HFpEF.二甲双胍对 T2D 诱导的 MAM 钙解偶联和糖尿病 HFpEF 早期小鼠模型收缩功能障碍的影响。
Int J Mol Sci. 2022 Mar 25;23(7):3569. doi: 10.3390/ijms23073569.
3
Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence.
二甲双胍在心力衰竭中的作用：从病理生理机制到临床证据
Biomolecules. 2021 Dec 4;11(12):1834. doi: 10.3390/biom11121834.
4
Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?钠-葡萄糖协同转运蛋白2抑制剂与二甲双胍作为2型糖尿病一线治疗药物的比较：是时候进行一场变革了吗？
Cardiovasc Drugs Ther. 2023 Apr;37(2):315-321. doi: 10.1007/s10557-021-07249-0. Epub 2021 Sep 3.
5
Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors.钠-葡萄糖协同转运蛋白2抑制剂的心血管效应及机制
Chronic Dis Transl Med. 2020 Aug 15;6(4):239-245. doi: 10.1016/j.cdtm.2020.07.002. eCollection 2020 Dec.
6
Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?二甲双胍在2型糖尿病现代管理中处于什么地位？
Pharmaceuticals (Basel). 2020 Nov 27;13(12):427. doi: 10.3390/ph13120427.
7
Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus.2型糖尿病中SGLT2（钠-葡萄糖协同转运蛋白2）抑制剂心血管益处的循证临床综述
Cureus. 2020 Aug 11;12(8):e9655. doi: 10.7759/cureus.9655.